Brensocatib is the first approved therapy for non–cystic fibrosis bronchiectasis and the first dipeptidyl peptidase 1 inhibitor for neutrophil-mediated diseases. The ASPEN trial showed brensocatib ...

Panelists discuss how the heterogeneity of bronchiectasis requires precise phenotyping and a treatable traits approach to address varying symptom profiles, from cough-predominant to shortness of ...

Please provide your email address to receive an email when new articles are posted on . New endpoints from the ASPEN trial were presented at the World Bronchiectasis Conference. FDA new drug ...

The designation was supported by data from the multicenter, double-blind, placebo-controlled phase 3 PROMIS-I study. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation ...

Please provide your email address to receive an email when new articles are posted on . For adults with bronchiectasis, $82,545 was the highest annual health care cost observed in a systematic review.

Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under the ...

FIRS organizations, including the American Thoracic Society, call for improving early detection of bronchiectasis. July 1, 2025 – According to the 2022 Global Impact of Respiratory Disease Report, the ...

Brensocatib, an experimental small-molecule inhibitor targeted to inflammation-regulating neutrophil serine proteases, may be a novel, nonantibiotic option for reducing exacerbations in patients with ...

CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial ...

Patients with bronchiectasis have frequent exacerbations that are thought to be related to neutrophilic inflammation. The activity and quantity of neutrophil serine proteases, including neutrophil ...